Tiru M, Jäätmaa E, Gillenius P, Askelöf P
Dev Biol Stand. 1985;61:469-75.
The intracerebral challenge test for determining the protective potency of pertussis vaccines has long been in use. In an effort to elucidate what antibodies are responsible for such protection, a study was undertaken to analyse serum antibodies against filamentous hemagglutinin, lymphocytosis promoting factor and agglutinogens. Conventional pertussis vaccines induced antibodies to FHA and agglutinogens in mice whereas no demonstrable antibodies to LPF were stimulated. By toxoiding LPF on cells with 0.4 per cent formaldehyde, preparations were obtained which induced anti-LPF antibodies in mice. This treatment however, resulted in considerable reduction in potency as judged by the intracerebral challenge test. Apparently the protective potency of pertussis vaccines in mice is based on the adjuvant properties of LPF and not its antigenic properties. An optimized schedule is outlined for the laboratory standardization of pertussis vaccines by measuring antibody responses and especially anti-LPF in mice. Highest titers were obtained in mice when the interval between immunization and booster injections was 28 days.
用于确定百日咳疫苗保护效力的脑内攻毒试验长期以来一直在使用。为了阐明何种抗体具有这种保护作用,开展了一项研究以分析针对丝状血凝素、淋巴细胞增多促进因子和凝集原的血清抗体。传统百日咳疫苗可在小鼠体内诱导产生针对丝状血凝素和凝集原的抗体,而未刺激产生可检测到的针对淋巴细胞增多促进因子的抗体。通过用0.4%甲醛对细胞上的淋巴细胞增多促进因子进行类毒素处理,获得了能在小鼠体内诱导产生抗淋巴细胞增多促进因子抗体的制剂。然而,根据脑内攻毒试验判断,这种处理导致效力大幅降低。显然,百日咳疫苗在小鼠体内的保护效力基于淋巴细胞增多促进因子的佐剂特性而非其抗原特性。通过测量小鼠的抗体反应,尤其是抗淋巴细胞增多促进因子抗体反应,概述了百日咳疫苗实验室标准化的优化方案。当免疫和加强注射之间的间隔为28天时,小鼠体内获得的抗体滴度最高。